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Background: Pregnant women with a history of acquired thrombotic thrombocytopenic purpura (TTP) are considered
at risk for disease recurrence and might be at risk for miscarriage, similar to other autoimmune disorders. However, the
exact entity of these risks and their causes are unknown. The aim of this study was to evaluate risk factors associated
with adverse pregnancy outcome, in terms of both gravidic TTP and miscarriage, in women affected by previous
acquired TTP.
Methods: We conducted a nested case? control study in women with a history of acquired TTP enrolled in the Milan
TTP registry from 1994 to October 2012, with strict inclusion criteria to reduce referral and selection bias.
Results: Fifteen out of 254 women with acquired TTP were included, namely four cases with gravidic TTP, five with
miscarriage, and six controls with uncomplicated pregnancy. In the cases, ADAMTS13 activity levels in the first trimester
were moderately-to-severely reduced (median levels <3% in gravidic TTP and median levels 20% [range 14-40%] in the
women with miscarriage) and anti-ADAMTS13 antibodies were invariably present, while in the control group
ADAMTS13 activity levels were normal (median 90%, range 40-129%), with absence of detectable anti-ADAMTS13
antibodies. Reduced levels of ADAMTS13 activity (<25%) in the first trimester were associated with an over 2.9-fold
increased risk for gravidic TTP and with an over 1.2-fold increased risk for miscarriage (lower boundary of the confidence
interval of the odds ratio). In addition, the presence of anti-ADAMTS13 antibodies during pregnancy was associated
with an over 6.6-fold increased risk for gravidic TTP and with an over 4.1-fold increased risk for miscarriage.
Conclusions: ADAMTS13 activity evaluation and detection of anti-ADAMTS13 antibody could help to predict the risk of
complications in pregnant women with a history of acquired TTP.
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Thrombotic Thrombocytopenic Purpura (TTP) is an acute,
life-threatening thrombotic microangiopathy caused by
deficient activity of the von Willebrand factor (VWF)
cleaving protease ADAMTS13 (a disintegrin and metallo-
protease with thrombospondin type 1 motif, 13th mem-
ber). The acquired form of the disease, accounting for
about 95% of all cases, is caused by autoantibodies di-
rected against the circulating metalloprotease which leads
to impaired cleavage of VWF [1].* Correspondence: flora.peyvandi@unimi.it
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unless otherwise stated.Similarly to many other autoimmune disorders, ac-
quired TTP generally affects young women, with a peak
of incidence in the third and fourth decades of life [2].
Almost half of TTP cases occur in women in childbearing
age and 12-25% of acute episodes are reported in associ-
ation with pregnancy or puerperium [3-7]. The associ-
ation between pregnancy and TTP is supported by
clinical observations and by the evidence that VWF-
ADAMTS13 balance varies during normal pregnancy.
VWF levels increase during the last trimester of normal
pregnancy and ADAMTS13 levels progressively reduce,
reaching values of as low as 25-30% in some women in
the third trimester [8-10].
Since pregnancy may trigger episodes of TTP, preg-
nant women with a history of TTP are considered to beis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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congenital TTP, a form caused by ADAMTS13 gene mu-
tations, almost all pregnancies are complicated by overt
TTP in the absence of prophylactic plasma infusion
[12,13]. For pregnant women with a history of acquired
TTP, the risk of recurrence is not well established and
no predictors are known. Accurate risk estimates are
lacking, and no data are available on the risk of miscar-
riage. Jiang Y et al. recently reported that recurrent TTP
complicating a subsequent pregnancy may be uncom-
mon and that other complications, such as preeclampsia,
may be increased [14]. These authors also reported two
cases of early foetal death, on a total of 16 pregnancies.
However, no estimates on risk factors were reported,
and ADAMTS13 assays were only performed in a mi-
nority. Another recent study by Scully M et al. did also
suggest that regular monitoring of ADAMTS13 activity
is advisable for achieving an uncomplicated pregnancy,
allowing for possible prophylactic correction [15]. How-
ever, no estimates on the predictive role of ADAMTS13
levels or anti-ADAMTS13 antibodies were reported.
With this background, the aim of this study was to
evaluate factors associated with adverse gravidic out-
come in women with a history of acquired TTP, in terms
of TTP recurrence or miscarriage. Since TTP is a rare
disease, many studies are based on selected patient series
referred to highly-specialized secondary-care centres.
This may result in ill-defined cohorts and estimates may
be biased. To minimize referral and selection bias, we ap-
plied strict inclusion criteria and a nested case? control
design.
Methods
We conducted a nested case ? control study of women
who became pregnant after the diagnosis of acquired
TTP. Among them, we contrasted data of women who
experienced a complicated pregnancy (i.e., cases of either
gravidic TTP or miscarriage) to those with an uncompli-
cated pregnancy (i.e., controls).
Patients
Patients included in this study were women with a his-
tory of acquired TTP referred to Angelo Bianchi Bonomi
Hemophilia and Thrombosis Centre, Fondazione IRCCS
Ca? Granda Ospedale Maggiore Policlinico, Milan (Italy),
and enrolled in the Milan TTP International Registry
from 1994 to October 2012, who subsequently became
pregnant. In order to be included in this study, the follow-
ing two criteria had to be met: (a) diagnosis of acquired
TTP; (b) a first confirmed pregnancy that occurred after
the diagnosis of acquired TTP and the inclusion in our
Registry. TTP was defined according to internationally
accepted criteria, that is by at least one episode with
the following characteristics: (i) thrombocytopenia; (ii)microangiopathic haemolytic anaemia; (iii) exclusion of
alternative explanations (such as the enterohaemorrhagic
form of haemolytic uraemic syndrome, catastrophic anti-
phospholipid antibodies syndrome, preeclampsia and re-
lated syndromes, sepsis, systemic inflammatory response
syndrome, disseminated intravascular coagulation, dis-
seminated malignancy and/or bone-marrow transplant-
ation associated TTP-like syndrome) [16]. Congenital
TTP was excluded by ADAMTS13 gene analysis in
patients with persistently low ADAMTS13 levels in re-
mission phase, despite disappearance of detectable anti-
ADAMTS13 antibodies.
Since the registry collects clinical and laboratory infor-
mation on TTP patients referred from different centres
and was not specifically designed for follow-up, it may
be affected by loss to follow-up, which precludes the es-
timate of absolute risks. Therefore, the study was re-
stricted to women for whom follow-up was available and
designed as a case ? control study, which allows the esti-
mation of relative risks. We searched for any docu-
mented pregnancy, using our digital database. Specific
information on pregnancies and their outcomes was ob-
tained by medical charts or by the administration of a
tailored questionnaire. The following variables were re-
corded: maternal age at the beginning of pregnancy,
gravidity, numbers of TTP episodes before pregnancy,
interval time between last TTP episode and conception,
duration and outcome of pregnancy, maternal and foetal
mortality, plasmatic ADAMTS13 activity levels and anti-
ADAMTS13 antibodies (performed on biological sam-
ples taken during pregnancy, before any plasma infusion
or exchange therapy).
Cases were women who experienced a complicated
pregnancy (either gravidic TTP or miscarriage), controls
those who had an uncomplicated pregnancy. Gravidic
TTP was defined as an acute TTP episode occurring
during pregnancy or in the post-partum period (40 days
after delivery). Miscarriage was defined as naturally-
occurring expulsion of the product of conception before
the 20th week of gestation, in the absence of thrombo-
cytopenia and/or haemolytic anaemia.
All patients included in the Registry signed an in-
formed consent, approved by the Ethics Committee of
our Hospital, following Helsinki Declaration statements.
Laboratory tests
ADAMTS13 activity was tested using a modified FRETS-
VWF73 assay [17]. ADAMTS13 activity values were ex-
pressed as percentage of pooled normal plasma standard
curve (arbitrarily considered as 100%). The lower limit of
sensitivity was 3% of the reference standard (pooled nor-
mal plasma); the lower value of the reference interval
(45%) was set at the 5th percentile of the distribution of
the values obtained in 72 healthy individuals.
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tected by Western blotting and, if positive, quantified by
an ELISA assay. Western blotting was performed as
reported, with minor modifications [18]. Conditioned
media of cells producing recombinant ADAMTS13
(100 ng/lane) were run on 7% sodium dodecyl sulphate
polyacrylamide gel electrophoresis and then were trans-
ferred onto pure nitrocellulose membrane (GE Health-
care, Buckinghamshire, UK). Thereafter, membranes
were incubated with citrated plasma (diluted 1/100) of
TTP patients as source of anti-ADAMTS13 antibody.
Bound antibodies were visualized using horseradish
peroxidase-labelled anti-human IgG (Sigma, St. Louis,
MO, USA) and the Opti-4CN substrate kit (BioRad,
Hercules, CA, USA). With regards to the ELISA assay
[19], a reference curve was obtained by serially diluting the
plasma of a TTP patient with a high anti-ADAMTS13 IgG
titre; the level of anti-ADAMTS13 IgG in sample plasmas
was then calculated as a percentage of the reference curve
(arbitrarily assigned a value of 100%). The cut-off for the
normal reference range was calculated on 74 healthy sub-
jects, and values higher than 2 standard deviations were
considered positive (anti-ADAMTS13 IgG > 1.18%).
Statistical analysis
Descriptive statistics were used for demographic and
clinical characteristics in each group.
We used odds ratios (OR), as an approximation of
relative risks for the variables of interest. The 95% confi-
dence interval (CI) of the OR was calculated according
to Woolf based on Poisson distributions and, when ap-
propriate, to Cornfield ? s approximate method [20].Figure 1 Study flow-chart for women selection. Abbreviations: TTP, ThroThe following variables were studied: age at pregnancy
(less than 30 years versus older); gravidity (primigravidae
versus multigravidae); TTP recurrence (non-recurrent
TTP versus recurrent); time from the last TTP episode
(conception within 24 months from the previous episode
of TTP versus more than 24 months); ADAMTS13 activ-
ity levels (less than 25% versus higher); anti-ADAMTS13
antibody (presence versus absence).
With regards to ADAMTS13-related measurements,
we contrasted cases and controls for ADAMTS13 activ-
ity levels in the first trimester (before any plasma infu-
sion or exchange therapy), for the following reasons: (i)
in the miscarriage group, pregnancy ended in the first
trimester; (ii) in the gravidic TTP cases, once severe
ADAMTS13 deficiency was detected, prophylactic treat-
ment was started thus subsequent samples were unsuit-
able for analysis. The cut-off of 25% for ADAMTS13
activity levels was chosen because below this value pa-
tients need closer monitoring since they are approaching
the critical level of 10% which is associated with the risk
of TTP recurrence.
Results
At the moment of the closing of the database (October
2012), the Milan TTP Registry included 254 women with
acquired TTP; of those, 17 met the strict inclusion cri-
teria of this study. One patient was excluded because of
pregnancy termination (reason unrelated to TTP) and
another one was excluded due to a history of cancer-
associated recurrent TTP. Therefore 15 women were in-
cluded in the analysis (Figure 1). Their main clinical
characteristics (age at pregnancy, gravidity, pregnancymbotic thrombocytopenic purpura.
Table 1 Demographic and clinical characteristics of women included in the study
Patient Maternal age
(years)
Gravidity Outcome of pregnancy
(onset, weeks)
Duration of pregnancy
(weeks)
Previous TTP episode
(gravidic)
1 26 M Gravidic TTP (21) 30 1 (1)
2 30 P Gravidic TTP (na) na 1
3 34 M Gravidic TTP (34) 34 2 (1)
4 24 P Gravidic TTP (30) 31 1
5 36 M Miscarriage 10 2 (1)
6 38 M Miscarriage 9 1 (1)
7 26 M Miscarriage 6 1
8 32 P Miscarriage 3 1
9 32 P Miscarriage 8 1
10 36 P Uncomplicated 38 3
11 32 P Uncomplicated 37 3
12 29 P Uncomplicated 39 1
13 29 M Uncomplicated 38 1
14 34 P Uncomplicated 38 2
15 33 P Uncomplicated 36 4
Abbreviations: M Multigravida, P Primigravida, TTP Thrombotic thrombocytopenic purpura, na Not available.
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TTP) are reported in Table 1, while ADAMTS13-related
measurements are reported in Table 2. All women were
Caucasian; median age at pregnancy was 32 years (range
24 ? 38 years) and 9 were primigravidae; 6 had a history
of recurrent TTP; the median time between the previous
TTP episode and conception was 28 months (range 2?
107 months). All patients were affected by autoimmuneTable 2 ADAMTS13 activity levels and anti-ADAMTS13 antibo
Patient ADAMTS13 activity, by FRET
1 T 2 T 3 T
1 <3 <3 on PEX
2 <3 on PEX
3 na na <3
4 na na 6
5 40 Miscarriage
6 na Miscarriage
7 14 Miscarriage
8 na Miscarriage
9 20 Miscarriage
10 129 97 70
11 40 39 45
12 90 84 80
13 na na 73
14 64 96 68
15 90 na na
Abbreviations: WB Western blotting, T Trimester, P Positive, N Negative, PEX Plasma-TTP (detectable anti-ADAMTS13 antibodies at least once
in the patient? s history, before inclusion in the study); in all
women except patient 11, severe ADAMTS13 deficiency
(i.e., <10%) was detected in either acute or remission
phase, out of pregnancy.
According to pregnancy outcome, the cases were divided
in two groups, cases of gravidic TTP (n = 4) and cases
of miscarriage (n = 5), while women with uncomplicateddies during pregnancy of women included in the study
Anti-ADAMTS13 IgG, by WB (%, by ELISA)
1 T 2 T 3 T
P (4) P (5) on PEX
P (3) on PEX
na na P (7.5)
na na P (3.5)
P (2) Miscarriage
na Miscarriage
P (4.4) Miscarriage
na Miscarriage
P (<1.18) Miscarriage
N N N
N N N
N N N
na na N
N N N
N na na
exchange, na Not available.
Table 3 Demographic and clinical characteristics of women according to pregnancy outcome
Gravidic TTP
(n = 4)
Miscarriage
(n = 5)
Uncomplicated pregnancy
(n = 6)
Maternal age at pregnancy, median [range], years 28 [24 ? 34] 32 [26? 38] 33 [29 ? 36]
Primigravidae 2 2 5
History of recurrent TTP (>1 episode) 1 1 4
Months since last TTP episode, median [range] 29 [20? 107] 17 [2? 38] 35 [5? 70]
ADAMTS13 activity (%) in the first trimester, median [range] (available) <3 (2) 20 [14 ? 40] (3) 90 [40 ? 129] (5)
Positive anti-ADAMTS13 antibodies in the first trimester (available) 2 (2) 3 (3) 0 (5)
Positive anti-ADAMTS13 antibodies in any trimester (available) 4 (4) 3 (3) 0 (6)
Figure 2 ADAMTS13 activity levels in the first trimester
according to pregnancy outcomes. Abbreviations: TTP, Thrombotic
thrombocytopenic purpura. For women with multiple tests, mean
values are reported.
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characteristics of cases and controls are reported in
Table 3.
Gravidic TTP recurrences developed in the second or
third trimester, while all five miscarriages occurred in
the first trimester (i.e., by 13th +1 gestational week).
ADAMTS13 activity levels in the first trimester were sig-
nificantly reduced in the cases of gravidic TTP, with me-
dian levels <3%, while ADAMTS13 deficiency was less
severe in the cases of miscarriage, with median levels of
20% (range 14-40%). Anti-ADAMTS13 antibodies resulted
to be invariably present in either group of cases, with me-
dian anti-ADAMTS13 IgG levels of 4% (range 3? 7.5%) in
women with gravidic TTP and 2% (range <1.18-4.4%) in
the miscarriage group. In the control group of women
with uncomplicated pregnancies ADAMTS13 activity
levels were normal in the first trimester (median 90%,
range 40-129%) and remained above 39% until delivery,
with absence of detectable anti-ADAMTS13 antibodies
(Figure 2).
Tables 4 and 5 show the odds ratios for the variables
that were included, indicating the associated relative risk
of a complicated pregnancy (either gravidic TTP or mis-
carriage). The highest odds ratios were associated with
reduced ADAMTS13 activity levels (below 25%) in the
first trimester, with lower boundary of the confidence
interval of the odds ratio over 2.9 for gravidic TTP (OR ∞,
95% CI 2.9 to ∞) and over 1.2 for miscarriage (OR ∞, 95%
CI 1.2 to ∞), and with the presence of anti-ADAMTS13
antibodies during pregnancy, with lower boundary of the
confidence interval of the odds ratio over 6.6 for gravidic
TTP (OR ∞, 95% CI 6.6 to ∞) and over 4.1 for miscarriage
(OR ∞, 95% CI 4.1 to ∞). We found that young women
(<30 years) had a higher risk for gravidic TTP than older
women (OR 6.0, 95% CI 0.4 to 101.6). Primigravidae had a
lower risk for both gravidic TTP (OR 0.2, 95% CI 0.01 to
3.7) and miscarriage (OR 0.1, 95% CI 0.01 to 2.2) than
multigravidae. Women with a single previous episode of
TTP were at higher risk for both gravidic complications
than women with multiple TTP events (gravidic TTP OR
6.0, 95% CI 0.4 to 101.6; miscarriage OR 8, 95% CI 0.5 to127.9). Conception before 24 months from the previous
TTP episode conferred a highly elevated risk for miscar-
riage (OR 20, 95% CI 0.9 to 429.9).
None of the 15 women received regular prophylactic
plasma infusion or exchange during gestation, as part of a
planned pregnancy; prophylactic plasma-exchange was per-
formed after detection of severely deficient ADAMTS13
activity levels (i.e., <10%) in patients 1 and 2 but, neverthe-
less, they developed gravidic TTP. Almost half of the cases
Table 4 Risk estimates for gravidic TTP associated with demographic and clinical variables
Gravidic TTP
(n = 4)
Uncomplicated pregnancy
(n = 6)
OR (95% CI)
Age≤ 30 years 3 2 6.0 (0.4 ? 101.6)
Age >30 years 1 4 ref
Primigravidae 2 5 0.2 (0.01 ? 3.7)
Multigravidae 2 1 ref
Non-recurrent TTP 3 2 6.0 (0.4 ? 101.6)
Recurrent TTP 1 4 ref
Time from previous TTP ≤24 months 1 1 1.7 (0.08 ? 37.7)
Time from previous TTP >24 months 3 5 ref
ADAMTS13 activity <25% in the first trimester* 2 0 ∞ (2.9 - ∞)
ADAMTS13 activity ≥25% in the first trimester* 0 5 ref
Positive anti-ADAMTS13 antibodies in any trimester 4 0 ∞ (6.6 - ∞)
Negative anti-ADAMTS13 antibodies in any trimester 0 6 ref
*ADAMTS13 activity levels in the first trimester were available in 2 cases and 5 controls.
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have had a history of previous gravidic TTP, in contrast
with none of the controls.
None of the 15 women had a history of poliabortivity
and, among the cases of miscarriage, only one woman
had had a single previous miscarriage (before the first
TTP episode).
The outcome of pregnancy in the complicated preg-
nancies was poor, for in one case both the mother and
her foetus died during TTP recurrence (patient 2); six
foetuses died, due to miscarriage occurring either before
or during gravidic TTP (patient 2).
Discussion
We conducted a study on clinical factors associated
with adverse gravidic outcome in women with a historyTable 5 Risk estimates for miscarriage associated with demog
Miscarr
(n =
Age≤ 30 years 1
Age >30 years 4
Primigravidae 2
Multigravidae 3
Non-recurrent TTP 4
Recurrent TTP 1
Time from previous TTP ≤24 months 4
Time from previous TTP >24 months 1
ADAMTS13 activity <25% in the first trimester* 2
ADAMTS13 activity ≥25% in the first trimester* 1
Positive anti-ADAMTS13 antibodies in the first trimester* 3
Negative anti-ADAMTS13 antibodies in the first trimester* 0
*ADAMTS13 activity levels and anti-ADAMTS13 antibodies in the first trimester wereof acquired TTP. To avoid bias associated with studies
on rare disorders conducted in referral centres and
registries, we applied the strictest inclusion criteria and a
nested case ? control design.
The strongest predictors of poor gravidic outcome were
reduced levels of ADAMTS13 activity below 25% in the
first trimester and the presence of anti-ADAMTS13 anti-
bodies, both for gravidic TTP recurrence and miscarriage.
Published data from case series and one prospective co-
hort study have suggested that low levels of ADAMTS13
are associated with poor pregnancy outcome, but no
risk estimates were available [15,21-25]. Moreover, anti-
ADAMTS13 antibodies are the hallmark of autoimmune
TTP but their predictive role in remission remains un-
clear, particularly in relation to added triggers, such as
pregnancy [18,26].raphic and clinical variables
iage
5)
Uncomplicated pregnancy
(n = 6)
OR (95% CI)
2 0.5 (0.03 ? 8.06)
4 ref
5 0.1 (0.01 ? 2.2)
1 ref
2 8.0 (0.5 ? 127.9)
4 ref
1 20.0 (0.9 ? 429.9)
5 ref
0 ∞ (1.2 - ∞)
5 ref
0 ∞ (4.1 - ∞)
5 ref
available in 3 cases and 5 controls.
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reduction of ADAMTS13 activity levels in association
with anti-ADAMTS13 antibodies before the gravidic
complication occurred. On the contrary, women with un-
complicated pregnancies showed near-normal ADAMTS13
activity levels till delivery, with no anti-ADAMTS13 anti-
bodies. Our results suggest that low ADAMTS13 activity
levels (<25%) in the first trimester in the presence of anti-
ADAMTS13 antibodies represent not only a risk factor for
TTP recurrence, but also for miscarriage. It is well known
that early changes in the maternal immunity system are
crucial for pregnancy outcome, since immune-tolerance
toward the semi-allogeneic foetus is necessary for physio-
logic progression of any gestation [27]. If this process does
not work correctly, gestation might be interrupted.
Women affected by other systemic autoimmune diseases
(such as systemic lupus erythematosus and systemic
sclerosis) have an increased risk of miscarriage and
such risk is associated with the activity of the disease.
Whether immune system dysregulation in acquired
autoimmune TTP and the presence of anti-ADAMTS13
antibodies might be responsible for increased risk of
miscarriage in these women, needs to be further investi-
gated. In our study miscarriage and gravidic TTP were
exclusive outcomes, which may be the result of women
with early miscarriage no longer being at risk to develop
gravidic TTP.
The results of this study support the hypothesis that
ADAMTS13 activity levels and anti-ADAMTS13 anti-
bodies are useful prognostic markers for gravidic com-
plications (TTP recurrence and miscarriage) in women
with previous acquired TTP. Therefore, we suggest to
strictly monitor all pregnant women with a history of ac-
quired TTP for both markers before and regularly dur-
ing their pregnancy. For all other variables included in
this study (age at pregnancy, gravidity, TTP recurrence,
time from the last TTP episode), the preliminary results
need to be further investigated.
Our study has some limitations. The number of preg-
nancies was limited, due to the strict design of the study,
and the low sample size renders many estimates impre-
cise. However, our choice of study design resulted in en-
hanced rigour and these estimates, despite less precise,
are also less biased. Moreover, we note that this was one
of the largest studies to date on the issue of TTP-related
gravidic complications and we are the first to present
risk estimates for this rare devastating disorder. Since we
are a tertiary-care centre for acute TTP, uncomplicated
pregnancies and miscarriages may not have been re-
ferred. Our nested case ? control design was specifically
aimed at reducing ensuing referral and selection bias.
Data on ADAMTS13 activity levels and anti-ADAMTS13
antibodies during pregnancy were not available for all
women.Conclusions
Reduced ADAMTS13 activity levels and the presence of
anti-ADAMTS13 antibodies represent risk factors for
poor outcome of pregnancy in women with a history of
acquired TTP. Given the desire of maternity in many
women affected by TTP at a young age, and the poten-
tially severe consequences of TTP during pregnancy,
these results may be useful to tailor future therapeutic
strategies in these women.
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